Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2008 2
2009 2
2010 1
2011 1
2012 4
2013 2
2014 3
2015 2
2016 5
2017 5
2018 4
2019 7
2020 4
2021 6
2022 5
2023 6
2024 13
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis.
Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, Giménez-Richarte Á, Ramos-Rincón JM, Belinchón-Romero I. Sánchez-García V, et al. Among authors: belinchon romero i. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):1971-1990. doi: 10.1111/jdv.19238. Epub 2023 Jun 13. J Eur Acad Dermatol Venereol. 2023. PMID: 37262303 Review.
[Nail involvement in leprosy].
Belinchón Romero I, Ramos Rincón JM, Reyes Rabell F. Belinchón Romero I, et al. Actas Dermosifiliogr. 2012 May;103(4):276-84. doi: 10.1016/j.ad.2011.07.011. Epub 2011 Nov 3. Actas Dermosifiliogr. 2012. PMID: 22056258 Free article. Review. Spanish.
Top-50 cited articles on cysticercosis and neurocysticercosis.
Gonzalez-Alcaide G, Sosa N, Valero-Samper F, Belinchon-Romero I, Ramos-Rincon JM. Gonzalez-Alcaide G, et al. Among authors: belinchon romero i. Medicine (Baltimore). 2024 Mar 1;103(9):e37268. doi: 10.1097/MD.0000000000037268. Medicine (Baltimore). 2024. PMID: 38428894 Free PMC article.
Coding of Dermatologic Diagnoses: An Unresolved Issue.
Belinchón Romero I. Belinchón Romero I. Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):765. doi: 10.1016/j.ad.2018.07.004. Epub 2018 Jul 24. Actas Dermosifiliogr (Engl Ed). 2018. PMID: 30053996 English, Spanish. No abstract available.
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A, Santos-Alarcón S, Sahuquillo-Torralba A, Rivera-Díaz R, Belinchón-Romero I, Ruiz-Genao D, Romero-Maté A, Ruiz-Villaverde R, Ferran-Farrés M, Gallardo-Hernández F, Almenara-Blasco M, Suarez-Perez JA, González-Cantero Á, Martínez-Lorenzo E, Fernández-Armenteros JM, Del Alcázar-Viladomiu E, García-Latasa J, Rocamora-Durant V, Ara-Martín M, Mateu-Puchades A, Llamas-Velasco M, Vilarrasa E, Velasco-Pastor M, De la Cueva P, Carrascosa JM, Magdaleno-Tapial J. Martorell A, et al. Among authors: belinchon romero i. Actas Dermosifiliogr. 2024 Mar 6:S0001-7310(24)00187-X. doi: 10.1016/j.ad.2024.02.030. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 38452889 English, Spanish.
The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease.
Olveira A, Augustin S, Benlloch S, Ampuero J, Suárez-Pérez JA, Armesto S, Vilarrasa E, Belinchón-Romero I, Herranz P, Crespo J, Guimerá F, Gómez-Labrador L, Martín V, Carrascosa JM. Olveira A, et al. Among authors: belinchon romero i. Life (Basel). 2023 Feb 2;13(2):419. doi: 10.3390/life13020419. Life (Basel). 2023. PMID: 36836776 Free PMC article. Review.
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M, Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Berenguer-Ruiz S, et al. Among authors: belinchon romero i. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2517-2525. doi: 10.1111/jdv.19468. Epub 2023 Sep 1. J Eur Acad Dermatol Venereol. 2023. PMID: 37625815
52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
Melgosa Ramos FJ, Mateu Puchades A, Matáix-Díaz J, Schneller-Pavelescu L, Belinchón-Romero I, Santos Alarcón S. Melgosa Ramos FJ, et al. Among authors: belinchon romero i. Actas Dermosifiliogr. 2024 Jul-Aug;115(7):722-726. doi: 10.1016/j.ad.2023.08.019. Epub 2024 Mar 29. Actas Dermosifiliogr. 2024. PMID: 38556201 Free article. English, Spanish.
61 results